Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...

A Relative Strength Rating upgrade for Takeda Pharmaceutical ADR shows improving technical performance. Will it continue?

Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive ...

Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and ...

Takeda Pharmaceutical (TSE:4502) has drawn investor attention after recent share price moves, with the stock showing different return profiles over the past week, month, past 3 months, and year. See ...

Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda.

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...

Takeda Pharmaceutical (NYSE:TAK) operates globally in healthcare, focusing on specialty medicines, biologics, and clinical ...

XOMA Royalty (XOMA) and Takeda (TAK) stock in focus as the companies ink a new royalty deal and armed an existing agreement.

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical ...

Takeda Pharmaceutical struck one of the biggest life science deals of 2022, acquiring a clinical-stage Nimbus Therapeutics drug addressing a promising new target for autoimmune disorders. Other than ...